SARC 006 : Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors

1 Pediatric Oncology Branch, NCI, CCR, Bethesda, MD, USA 2 Biostatistics and Data Management Section, NCI, Bethesda, MD, USA 3 University of California, San Francisco, San Francisco, CA, USA 4 University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA 5 MD Anderson Cancer Center, Houston, TX, USA 6 University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, USA 7 University of Iowa Hospital and Clinics, Iowa City, IA, USA 8 Indiana University, Indianapolis, IN, USA 9 University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA 10The Royal Marsden NHS Foundation Trust, Institute of Cancer Research, London, UK 11Levine Cancer Center, Charlotte, NC, USA 12Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, USA 13University of Minnesota Masonic Children’s Hospital, Minneapolis, MN, USA 14Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA 15Women’s Malignancies Branch, NCI, Bethesda, MD, USA 16SARC, Ann Arbor, MI, USA 17University of Utah, Salt Lake City, UT, USA

[1]  J. Blay,et al.  sarcomaFull-dose neoadjuvant anthracycline + ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall: Interim analysis of a prospective randomized trial , 2016 .

[2]  S. Peltonen,et al.  Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Dafydd G. Thomas,et al.  SARC009: Phase 2 study of dasatinib in patients with previously treated, high‐grade, advanced sarcoma , 2016, Cancer.

[4]  D. Reinke,et al.  A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma. , 2015, European journal of cancer.

[5]  D. Liebner The indications and efficacy of conventional chemotherapy in primary and recurrent sarcoma , 2015, Journal of surgical oncology.

[6]  A. Kim,et al.  Current Treatment Options for Malignant Peripheral Nerve Sheath Tumors , 2015, Current Treatment Options in Oncology.

[7]  V. Zagonel,et al.  Adjuvant and neoadjuvant chemotherapy for soft tissue sarcomas. , 2013, Current medicinal chemistry.

[8]  K. S. Hall,et al.  Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1 , 2012, Neuro-oncology.

[9]  W. Marsden I and J , 2012 .

[10]  S. Martinez,et al.  Influence of Specialty and Clinical Experience on Treatment Sequencing in the Multimodal Management of Soft Tissue Extremity Sarcoma , 2012, Annals of Surgical Oncology.

[11]  Andrea Ferrari,et al.  Soft tissue sarcoma across the age spectrum: A population‐based study from the surveillance epidemiology and end results database , 2011, Pediatric blood & cancer.

[12]  P. Wolkenstein,et al.  Evolving Pattern with Age of Cutaneous Signs in Neurofibromatosis Type 1: A Cross-Sectional Study of 728 Patients , 2011, Dermatology.

[13]  L. Mariani,et al.  Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups. , 2011, European journal of cancer.

[14]  M. van Glabbeke,et al.  First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  Paul A Meyers,et al.  Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  L. Qin,et al.  Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Citrin,et al.  The role of radiation therapy in the management of sarcomas. , 2008, The Surgical clinics of North America.

[18]  宏和 田中,et al.  膵癌を伴った縦隔原発Malignant Peripheral Nerve Sheath Tumor(MPNST)の一例 , 2007 .

[19]  S. Devesa,et al.  Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases , 2006, International journal of cancer.

[20]  A. Ferrari,et al.  Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  K. Khosrotehrani,et al.  Subcutaneous neurofibromas are associated with mortality in neurofibromatosis 1: A cohort study of 703 patients , 2005, American journal of medical genetics. Part A.

[22]  R. Lothe,et al.  Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Tripp,et al.  Malignant Peripheral Nerve Sheath Tumor: A Comparison of Grade, Immunophenotype, and Cell Cycle/Growth Activation Marker Expression in Sporadic and Neurofibromatosis 1-Related Lesions , 2003, The American journal of surgical pathology.

[24]  D. Evans,et al.  Malignant peripheral nerve sheath tumours in neurofibromatosis 1 , 2002, Journal of medical genetics.

[25]  V. Bramwell,et al.  Dose-intensive chemotherapy in advanced adult soft tissue sarcoma , 2002, Expert review of anticancer therapy.

[26]  D. Gutmann,et al.  International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. , 2002, Cancer research.

[27]  M. Kattan,et al.  Postoperative nomogram for 12-year sarcoma-specific death. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  D. Evans,et al.  Malignant peripheral nerve sheath tumors in neurofibromatosis 1. , 2001 .

[29]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[30]  K. Sundby Hall,et al.  Chemotherapy in soft tissue sarcomaThe Scandinavian Sarcoma Group experience , 2004, Acta orthopaedica Scandinavica. Supplementum.

[31]  M. Campanacci Malignant Peripheral Nerve Sheath Tumor (MPNST) , 1999 .

[32]  Y. Ozisik,et al.  Treatment of advanced refractory sarcomas with ifosfamide and etoposide combination chemotherapy. , 1998, Cancer investigation.

[33]  J. Neal,et al.  Malignant Peripheral Nerve Sheath Tumors (Malignant Schwannomas) in Children , 1992, The American journal of surgical pathology.

[34]  R. Wittes,et al.  Therapeutic response in phase I trials of antineoplastic agents. , 1986, Cancer treatment reports.

[35]  B. Scheithauer,et al.  Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases , 1986, Cancer.